Top 3 observations of the first-in-human study with novel PCSK9 base editing medicine

3' education - Nov. 16, 2023 - Andrew Bellinger, MD, PhD - Boston, MA, US

Educational information

This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, US.

Faculty

Andrew Bellinger, MD, PhD is chief scientific officer of Verve Therapeutics and a general cardiologist at Brigham and Women’s Hospital.

Disclosures

This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.

Read our summary of this study

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.